Lonza Group Ltd (LZAGY)
62.99
+1.32
(+2.14%)
USD |
OTCM |
Nov 01, 16:00
Lonza Group Enterprise Value: 47.47B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 47.47B |
| October 31, 2024 | 46.52B |
| October 30, 2024 | 46.64B |
| October 29, 2024 | 47.15B |
| October 28, 2024 | 47.89B |
| October 25, 2024 | 48.14B |
| October 24, 2024 | 48.29B |
| October 23, 2024 | 46.95B |
| October 22, 2024 | 47.06B |
| October 21, 2024 | 47.16B |
| October 18, 2024 | 48.09B |
| October 17, 2024 | 47.84B |
| October 16, 2024 | 46.70B |
| October 15, 2024 | 46.79B |
| October 14, 2024 | 47.41B |
| October 11, 2024 | 46.31B |
| October 10, 2024 | 45.87B |
| October 09, 2024 | 46.62B |
| October 08, 2024 | 46.42B |
| October 07, 2024 | 46.30B |
| October 04, 2024 | 46.39B |
| October 03, 2024 | 47.04B |
| October 02, 2024 | 47.08B |
| October 01, 2024 | 47.73B |
| September 30, 2024 | 47.60B |
| Date | Value |
|---|---|
| September 27, 2024 | 48.01B |
| September 26, 2024 | 48.20B |
| September 25, 2024 | 47.19B |
| September 24, 2024 | 47.71B |
| September 23, 2024 | 47.56B |
| September 20, 2024 | 47.14B |
| September 19, 2024 | 48.18B |
| September 18, 2024 | 47.42B |
| September 17, 2024 | 47.88B |
| September 16, 2024 | 49.23B |
| September 13, 2024 | 49.23B |
| September 12, 2024 | 48.20B |
| September 11, 2024 | 48.95B |
| September 10, 2024 | 48.82B |
| September 09, 2024 | 48.20B |
| September 06, 2024 | 47.88B |
| September 05, 2024 | 47.49B |
| September 04, 2024 | 47.94B |
| September 03, 2024 | 47.68B |
| August 30, 2024 | 49.18B |
| August 29, 2024 | 49.14B |
| August 28, 2024 | 49.52B |
| August 27, 2024 | 49.29B |
| August 26, 2024 | 49.24B |
| August 23, 2024 | 49.53B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
26.53B
Minimum
Oct 30 2023
66.93B
Maximum
Aug 27 2021
44.67B
Average
44.45B
Median
Enterprise Value Benchmarks
| AC Immune SA | 102.01M |
| CRISPR Therapeutics AG | 3.839B |
| Addex Therapeutics Ltd | 7.218M |
| NLS Pharmaceutics Ltd | 14.90M |
| Molecular Partners AG | 26.06M |
Enterprise Value Related Metrics
| Earnings Yield | 1.41% |
| Operating Earnings Yield | 2.11% |
| Normalized Earnings Yield | 1.587 |